A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Saruparib (Primary) ; Saruparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 16 Jan 2025 Planned End Date changed from 10 Jun 2026 to 1 Sep 2026.
- 16 Jan 2025 Planned primary completion date changed from 10 Jun 2026 to 1 Sep 2026.
- 16 Jan 2025 Planned initiation date changed from 18 Dec 2024 to 3 Mar 2025.